Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis
Extra-skeletal manifestations (EMs) of ankylosing spondylitis (AS) can occur and proceed in parallel with inflammatory changes in the joints and spine and often dominate in the clinical picture of AS, determining its high activity and significantly worsening the quality of life in patients. In a num...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2019-10-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/968 |
| _version_ | 1797876713821044736 |
|---|---|
| author | A. B. Demina |
| author_facet | A. B. Demina |
| author_sort | A. B. Demina |
| collection | DOAJ |
| description | Extra-skeletal manifestations (EMs) of ankylosing spondylitis (AS) can occur and proceed in parallel with inflammatory changes in the joints and spine and often dominate in the clinical picture of AS, determining its high activity and significantly worsening the quality of life in patients. In a number of cases, EMs are characterized by an insufficient response to standard anti-inflammatory therapy for back pain, arthritis, and enthesitis; and there is a need to prescribe another class of drugs.The review highlights the results of studies evaluating the efficacy of golimumab (GLM) in treating EMs in patients with AS: uveitis (GO-EASY Study) and ulcerative colitis (UC) (PURSUIT-SC, PURSUIT-M studies). Analysis of these studies have shown the high efficacy and safety of GLM in reducing the clinical manifestations of AS and in preventing the exacerbations of uveitis and UC. However, despite the successes achieved in treating AS and its EMs, there are many unresolved issues, including those related to the elaboration of optimal treatment regimens, which required longer observational studies with a large sample size. |
| first_indexed | 2024-04-10T02:06:59Z |
| format | Article |
| id | doaj.art-fd529648d70b46cab3a78b99c0158938 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:06:59Z |
| publishDate | 2019-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-fd529648d70b46cab3a78b99c01589382023-03-13T08:39:27ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2019-10-0113411011510.14412/1996-7012-2019-4-110-1152220Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitisA. B. Demina0ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»Extra-skeletal manifestations (EMs) of ankylosing spondylitis (AS) can occur and proceed in parallel with inflammatory changes in the joints and spine and often dominate in the clinical picture of AS, determining its high activity and significantly worsening the quality of life in patients. In a number of cases, EMs are characterized by an insufficient response to standard anti-inflammatory therapy for back pain, arthritis, and enthesitis; and there is a need to prescribe another class of drugs.The review highlights the results of studies evaluating the efficacy of golimumab (GLM) in treating EMs in patients with AS: uveitis (GO-EASY Study) and ulcerative colitis (UC) (PURSUIT-SC, PURSUIT-M studies). Analysis of these studies have shown the high efficacy and safety of GLM in reducing the clinical manifestations of AS and in preventing the exacerbations of uveitis and UC. However, despite the successes achieved in treating AS and its EMs, there are many unresolved issues, including those related to the elaboration of optimal treatment regimens, which required longer observational studies with a large sample size.https://mrj.ima-press.net/mrj/article/view/968анкилозирующий спондилитвнескелетные проявленияувеитязвенный колитингибиторы фактора некроза опухоли αголимумаб |
| spellingShingle | A. B. Demina Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis Современная ревматология анкилозирующий спондилит внескелетные проявления увеит язвенный колит ингибиторы фактора некроза опухоли α голимумаб |
| title | Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis |
| title_full | Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis |
| title_fullStr | Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis |
| title_full_unstemmed | Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis |
| title_short | Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis |
| title_sort | golimumab in the treatment of extra skeletal manifestations of ankylosing spondylitis |
| topic | анкилозирующий спондилит внескелетные проявления увеит язвенный колит ингибиторы фактора некроза опухоли α голимумаб |
| url | https://mrj.ima-press.net/mrj/article/view/968 |
| work_keys_str_mv | AT abdemina golimumabinthetreatmentofextraskeletalmanifestationsofankylosingspondylitis |